

SCHWARTZ NORMAN D  
Form 4  
June 14, 2010

**FORM 4**

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
SCHWARTZ NORMAN D

2. Issuer Name and Ticker or Trading Symbol  
BIO RAD LABORATORIES INC  
[BIO, BIO.B]

5. Relationship of Reporting Person(s) to Issuer  
  
(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction  
(Month/Day/Year)  
06/10/2010

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
CEO

C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

HERCULES, CA 94547

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |   |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|---|
|                                 |                                      |  |                                | (A) or (D)  | Price   |  |  |   |
|                                 |                                      |  |                                | Code  | V   | Amount   |  |   |
| Bio-Rad A Common Stock          | 04/29/2010                           |  | G                              | V   | 8,086   | A  | \$ 0 270,206                               | D |
| Bio-Rad B Common Stock          | 02/12/2010                           |  | G                              | V   | 274   | A  | \$ 0 77,248                                | D |
| Bio-Rad B Common Stock          | 06/10/2010                           |  | M                              |   | 2,400<br>(1)  | A  | \$ 0 79,648                                | D |

Edgar Filing: SCHWARTZ NORMAN D - Form 4

|                              |            |  |   |   |     |   |      |           |   |   |
|------------------------------|------------|--|---|---|-----|---|------|-----------|---|---|
| Bio-Rad B<br>Common<br>Stock | 02/12/2010 |  | G | V | 274 | A | \$ 0 | 11,874    | I | By Spouse<br>(2)                          |
| Bio-Rad B<br>Common<br>Stock |            |  |   |   |     |   |      | 4,060,054 | I | By Blue<br>Raven<br>Partners,<br>L.P. (3) |
| Bio-Rad B<br>Common<br>Stock |            |  |   |   |     |   |      | 13,726    | I | By DANSA<br>Partnership<br>(4)            |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Underlying Securities (Instr. 3 and 4) |                            |
|--|--|--------------------------------------|--|--------------------------------|--|--|---|--|----------------------------|
|  |  |                                      |  |                                |  | Date Exercisable   | Expiration Date   | Title  | Amount or Number of Shares |
| Restricted Stock Units                     | (5)  | 06/10/2010                           |  | M                              | 2,400  | (6)  | (6)   | Bio-Rad B Common Stock                             | 2,400                      |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |         |       |
|--|---------------|-----------|---------|-------|
|  | Director      | 10% Owner | Officer | Other |
| SCHWARTZ NORMAN D<br>C/O BIO-RAD LABORATORIES, INC.<br>1000 ALFRED NOBEL DRIVE<br>HERCULES, CA 94547 | X             | X         | CEO     |       |

## Signatures

Norman D.  
Schwartz

06/14/2010

    Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares of Class B common stock acquired on the vesting of restricted stock units.
  - (2) The reporting person disclaims beneficial ownership of these shares.
  - (3) The shares are held by a limited partnership of which the reporting person is a limited and general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
  - (4) The shares are held by a limited partnership of which the reporting person is a limited partner.
  - (5) Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class B common stock.
  - (6) The restricted stock units vest in five equal annual installments beginning June 10, 2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.